EUVIMEDObjevte EUVIMED
Klinische StudieOpen access · CC BY-NC-ND 4.0

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers

Owen Scudamore iD, Sven Wind iD, Rolf Grempler iD, Habib Esmaeili iD, Fabian Müller iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-07 · 46 (7)

DOI: 10.1002/phar.70182 ↗

At a glance

Klinische Studie in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2026-06-21. Written by Owen Scudamore and 4 co-authors. Institution: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. Major MEDLINE topics: Itraconazole, Cytochrome P-450 CYP3A Inhibitors, Protein Kinase Inhibitors. 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Boehringer Ingelheim.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild‐type epidermal growth factor receptor (EGFR), thereby minimizing associated toxicities. Oxidative hepatic metabolism of zongertinib in vitro is principally driven by cytochrome P450 (CYP) 3A. It is necessary, therefore, to assess the effect of a strong CYP3A inhibitor on the pharmacokinetics of zongertinib in humans.

Objective

This study investigated the effect of multiple oral doses of the strong CYP3A inhibitor and regulatory‐recommended probe inhibitor of P‐glycoprotein (P‐gp), itraconazole, on the pharmacokinetics of a single dose of zongertinib in healthy male participants.

Methods

This open‐label, two‐period, fixed‐sequence, clinical drug–drug interaction study assessed the pharmacokinetics of a 15 mg oral dose of zongertinib in the absence and presence of multiple oral doses of itraconazole. The extent of drug–drug interaction was estimated using the adjusted geometric mean (gMean) ratios (90% confidence intervals [CIs]) for the test (T) treatment (zongertinib and itraconazole) vs. the reference (R) treatment (zongertinib alone). Primary endpoints were the area under the plasma concentration–time curve from time 0 to infinity (AUC 0–∞ ) and the maximum measured plasma concentration (C max ) of zongertinib. The secondary pharmacokinetic endpoint was AUC for zongertinib from time 0 to the last quantifiable time point (AUC 0–tz ).

Results

Sixteen participants received zongertinib alone (Period 1, R), followed by co‐administration with itraconazole (Period 2, T). In terms of zongertinib exposure, the gMean ratio of T to R was 141.2% (90% CI: 126.3–157.7%) for AUC 0–∞ , 142.8% (90% CI: 126.0–161.9%) for AUC 0–tz , and 126.9% (90% CI: 106.6–151.0%) for C max .

Conclusion

Co‐administration with itraconazole resulted in a mild increase in total exposure to zongertinib that was not considered clinically relevant given its wide therapeutic window. These data indicate that the approved 120 mg dose of zongertinib can be administered without dose adjustment in combination with CYP3A/P‐gp inhibitors.

Subjects

MeSH terms (MEDLINE)

ItraconazoleCytochrome P-450 CYP3A InhibitorsProtein Kinase InhibitorsHumansMaleDrug InteractionsAdultAdministration, OralYoung AdultArea Under CurveMiddle AgedDose-Response Relationship, DrugAcrylamidesImidazolesPyrimidines

Author keywords

CYP3Adrug interactionsitraconazolepharmacokineticstyrosine kinase inhibitorszongertinib

Substances

ItraconazoleCytochrome P-450 CYP3A InhibitorsProtein Kinase InhibitorszongertinibAcrylamidesImidazolesPyrimidines

Authors and institutions

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
  • Staburo GmbH, Munich, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID profiles: Owen Scudamore, Sven Wind, Rolf Grempler, Habib Esmaeili, Fabian Müller

Funding

  • Boehringer Ingelheim

Cite

APA

Scudamore, O., Wind, S., Grempler, R., Esmaeili, H., & Müller, F. (2026). The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(7). https://doi.org/10.1002/phar.70182

Vancouver

Scudamore O, Wind S, Grempler R, Esmaeili H, Müller F. The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(7). doi:10.1002/phar.70182

BibTeX
@article{Scudamore2026,
  author = {Scudamore, Owen and Wind, Sven and Grempler, Rolf and Esmaeili, Habib and Müller, Fabian},
  title = {The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1002/phar.70182}
}
Start for free →